A股異動 | 新開源漲7%股價創半年新高 技術改進後PVP年產量可達到1.3萬噸
格隆匯7月22日丨新開源(300109.SZ)漲5.04%,報21.27源,總市值73億元,盤中一度漲超7%。新開源在機構調研時表示,公司目前在現廠址建設了兩條5000噸NVP生產線,通過技術改進後,PVP年產量可達到1.3萬噸。公司國內市場份額近50%,行業壁壘比較高,尤其是國內要求藥用輔料企業實行cGMP標準生產以後,新進入者甚少。另外公司客户粘性較高,下游的客户選擇了原料供應商後,一般不會輕易更換。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.